Making waves

Article

I would like to give a warm welcome to all of our readers and, particularly to those of you who have recently joined the many ophthalmologists across Europe who read our publication. I have been delighted by the response we have had to Ophthalmology Times Europe so far and I would like to thank you all for your very kind words of support and encouragement. We have tried to make Ophthalmology Times Europe a little different to other publications out there, not only in the world of ophthalmology, but across industries. By providing broad coverage of the industry and presenting arguments and ideas in an easily digestible format, it has been our mission to supply you with something that you enjoy reading.

So if you think we are missing something or if you would like to make your voice heard, please do get in touch. I am always happy to hear from you.

This month's feature, Wavefront technologies: what's best for your patient? embarks on a mission to help you find the wavefront treatment that will benefit your patient most. By profiling some of the technologies currently on the market, we have tried to give you a taste of what's out there and what impact, changing your approach to laser surgery, could have on your practice. Many studies have been published proving the benefits of wavefront treatment over conventional excimer laser surgery. However, the current argument is, of the wavefront technologies available, which one's best? There will always be issues relating to cost effectiveness and speed of treatment but take a look at the facts and make your judgement.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.